[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference",
    "summary": "PRINCETON, N.J., February 23, 2026--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference",
    "url": "https://finnhub.io/api/news?id=060fdec7bcb77e88413317fb77f8e1e20fc52f59451b3265d394e292d504ec63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771881360,
      "headline": "Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference",
      "id": 139188060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., February 23, 2026--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference",
      "url": "https://finnhub.io/api/news?id=060fdec7bcb77e88413317fb77f8e1e20fc52f59451b3265d394e292d504ec63"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Barclays began coverage of Bristol-Myers Squibb Company (NYSE:BMY) with an Overweight rating and a $75 price target. The analyst acknowledged that the company is approaching a difficult period, pointing to a “patent cliff” as exclusivity […]",
    "url": "https://finnhub.io/api/news?id=e1a2aedbef27b2ffb59065bf19cbf28599545b6185b3798b7aae78bcb8e51dbe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771870438,
      "headline": "Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential",
      "id": 139187365,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Barclays began coverage of Bristol-Myers Squibb Company (NYSE:BMY) with an Overweight rating and a $75 price target. The analyst acknowledged that the company is approaching a difficult period, pointing to a “patent cliff” as exclusivity […]",
      "url": "https://finnhub.io/api/news?id=e1a2aedbef27b2ffb59065bf19cbf28599545b6185b3798b7aae78bcb8e51dbe"
    }
  },
  {
    "ts": null,
    "headline": "What's in Store for These 5 Medical Companies This Earnings Season?",
    "summary": "IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.",
    "url": "https://finnhub.io/api/news?id=7884f2c87cb0f77ade9a77c1c8a5dc1a6fdc8ee80361015fff97667392aff78d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771855620,
      "headline": "What's in Store for These 5 Medical Companies This Earnings Season?",
      "id": 139185147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.",
      "url": "https://finnhub.io/api/news?id=7884f2c87cb0f77ade9a77c1c8a5dc1a6fdc8ee80361015fff97667392aff78d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia",
    "summary": "PRINCETON, N.J., February 23, 2026--Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia",
    "url": "https://finnhub.io/api/news?id=922c171c348c3cb391e7b33da3cf107bfe914c2f649699769a6ce86e702bc739",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771847940,
      "headline": "Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia",
      "id": 139183775,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., February 23, 2026--Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia",
      "url": "https://finnhub.io/api/news?id=922c171c348c3cb391e7b33da3cf107bfe914c2f649699769a6ce86e702bc739"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Reports Phase 2 Results for Reblozyl in Alpha-Thalassemia Patients",
    "summary": "Bristol Myers Squibb (NYSE:BMY) today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia in",
    "url": "https://finnhub.io/api/news?id=4b3efc4a47318a10b69ed8ce081eafbef944f721226be2a0e1b175269e5770b3",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771833881,
      "headline": "Bristol Myers Reports Phase 2 Results for Reblozyl in Alpha-Thalassemia Patients",
      "id": 139184295,
      "image": "",
      "related": "BMY",
      "source": "Benzinga",
      "summary": "Bristol Myers Squibb (NYSE:BMY) today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia in",
      "url": "https://finnhub.io/api/news?id=4b3efc4a47318a10b69ed8ce081eafbef944f721226be2a0e1b175269e5770b3"
    }
  },
  {
    "ts": null,
    "headline": "Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Raises Price Target to $75",
    "summary": "Piper Sandler  analyst David Amsellem   maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and raises the price target from $66 to $75.",
    "url": "https://finnhub.io/api/news?id=ef3053dab725e24fde398781149c1a1838a10c26b58b90875207fd0c57306cc5",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771833659,
      "headline": "Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Raises Price Target to $75",
      "id": 139184296,
      "image": "",
      "related": "BMY",
      "source": "Benzinga",
      "summary": "Piper Sandler  analyst David Amsellem   maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and raises the price target from $66 to $75.",
      "url": "https://finnhub.io/api/news?id=ef3053dab725e24fde398781149c1a1838a10c26b58b90875207fd0c57306cc5"
    }
  },
  {
    "ts": null,
    "headline": "2 Large-Cap Stocks on Our Buy List and 1 That Underwhelm",
    "summary": "Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.",
    "url": "https://finnhub.io/api/news?id=8aee9a3edae6246e379a598efda17d8adc3eec64836093ac4aaa454528d05749",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771822275,
      "headline": "2 Large-Cap Stocks on Our Buy List and 1 That Underwhelm",
      "id": 139183110,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.",
      "url": "https://finnhub.io/api/news?id=8aee9a3edae6246e379a598efda17d8adc3eec64836093ac4aaa454528d05749"
    }
  }
]